PDF
ePub
Citation
Print
Abstract
Lung cancer is the most common cause of death from neoplasms in Korea. Since the pathologic diagnosis is very important to determine the optimal treatment protocol of the patients, not only pathologists, but also oncologists, have an interest in the diagnosis of cancer. At the present time, immunohistochemical studies do more than play a supplementary role on the biopsied or excised specimens from cancer patients. Thus, I have reviewed the general principles and applications of immunohistochemistry on the histologic diagnosis of lung cancer.
References
1. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization. Tumors of the lung. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press;2004. p. 9–67.
2. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002; 26:1184–1197.
3. Guinee DG Jr, Fishback NF, Koss MN, Abbondanzo SL, Travis WD. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol. 1994; 102:406–414.
4. Folpe AL, Gown AM, Lamps LW, et al. Thyroid transforming factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol. 1999; 12:5–8.
5. Zamecnik J, Kodet R. Value of thyroid transforming factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases. Virchows Arch. 2002; 440:353–361.
6. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol. 2002; 26:767–773.
7. Lau SK, Desrochers MJ, Luthringer DJ. Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases. Mod Pathol. 2002; 15:538–542.
8. Shah RN, Badve S, Papreddy K, Schindler S, Laskin WB, Yeldandi AV. Expression of cytokeratin 20 in mucinous bronchioloalveolar carcinoma. Hum Pathol. 2002; 33:915–920.
9. Carella R, Deleonardi G, D'Errico A, et al. Immunohistochemical panels for differentiating epithelial malignant meso-thelioma from lung adenocarcinoma. Am J Surg Pathol. 2001; 25:43–50.
10. Nelson WG, Sun TT. The 50- and 58-kdalton keratin classes as molecular markers for stratified squamous epithelia: cell culture studies. J Cell Biol. 1983; 97:244–251.
11. Wang BY, Gil J, Kaufman D, Gan L, Kohtz DS, Burstein DE. P63 in pulmonary squamous neoplasms, and other pulmonary tumors. Hum Pathol. 2002; 33:921–996.
12. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991; 15:529–553.
13. Bostwick DG, Null WE, Holmes D, Weber E, Barchas JD, Bensch KG. Expression of opioid peptides in tumors. N Engl J Med. 1987; 317:1439–1443.
14. Cai YC, Banner B, Glickman J, Odze RD. Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors. Hum Pathol. 2001; 32:1087–1093.
15. Bishopric GA Jr, Ordonez NG. Carcinoembryonic antigen in primary carcinoid tumors of the lung. Cancer. 1986; 58:1316–1320.
XML Download